DCAT Week ’17 Member Company Announcement Forum: Tracking the Pharma Manufacturing Value Chain

Senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions, at the DCAT Member Company Announcement Forum at DCAT Week ’17. DCAT Value Chain Insights highlights the latest developments.

Developments in Drug-Substance Manufacturing
Noramco CEO Discusses Strategy as Stand-Alone Company

Patheon Integrates Former Roche API Manufacturing Facility

BioVectra Outlines API Manufacturing Expansion

Novasep Opens New Bioconjugation Facility for ADCs

Olon Highlights Integration of Infa

CMC Biologics Updates Acquisition by AGC Asahi Glass

Developments in Drug-Product Development and Manufacturing
Mayne Pharma Specifies Timeline for $80-Million Expansion

Catalent Integrates Pharmatek and Accucaps Acquisitions

Lubrizol’s Particle Sciences Expands Manufacturing

Developments in both Drug Substance and Drug Product Manufacturing:
Siegfried CEO Outlines Five-Year Strategic Plan

CordenPharma Expands Oligonucletides and Sterile Injectables

Developments in Packaging
Datwyler Outlines $100-Million Manufacturing Expansion

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Navigating the Supply-Chain Impacts of US Port Closings

By
The shutdown of ports on the US Gulf and East Coasts this week due to a labor strike had the potential for a major impact on the flow of US chemical shipments. With a strike now temporarily diverted, how would have chemical and pharma ingredient supply chains been affected?

Bio/Pharma Watchlist: Small-Molecule Drugs

By
Specialty small-molecule drugs are growing more than twice as fast as those of traditional small-molecule drugs. What are some key drugs contributing to this growth, and how is product innovation faring?

Pharma’s Innovations in Green Chemistry

By
As bio/pharma companies and their suppliers seek ways to improve their carbon footprint and meet sustainability targets, what have been recent noteworthy advances in green chemistry in small-molecule drug synthesis?

Generics Outlook: Small Molecules and Biosimilars

By
Small-molecule drugs dominate the global generics market, but biosimilars’ projected growth rate is double that of small-molecule drugs. Near-term projections and analysis of the generics and biosimilars market.